Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Summary of Changes Due To Recently Adopted Guidance (Detail)

v3.10.0.1
Summary of Significant Accounting Policies - Summary of Changes Due To Recently Adopted Guidance (Detail) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Mar. 31, 2018
Dec. 31, 2017
Sep. 30, 2017
Jun. 30, 2017
Mar. 31, 2017
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]                        
Prepaid Expense and Other Assets, Current         $ 5,153         $ 5,153    
Other assets $ 2,538       891       $ 2,538 891    
Assets 505,015       344,454       505,015 344,454    
Current pharma contract liability 927       1,406       927 1,406    
Long-term pharma contract liability 1,652       283       1,652 283    
Deferred income tax liability, net 22,457       6,688       22,457 6,688    
Stockholders' Equity Attributable to Parent 320,443       171,962       320,443 171,962 $ 162,316 $ 208,522
Liabilities and Equity 505,015       344,454       505,015 344,454    
Income Statement [Abstract]                        
Total Revenue 76,475 $ 69,097 $ 67,746 $ 63,423 61,422 $ 59,137 $ 62,264 $ 57,428 276,741 240,251 231,808  
Gross Profit 37,111 32,321 30,530 27,303 26,762 24,895 27,352 22,948 127,265 101,956 98,104  
Total operating expenses                 117,225 99,054 95,949  
Income from Operations                 10,040 2,902 2,155  
Interest expense                   5,540 9,998  
Other expense (income)                 (14) 12 0  
Income tax (benefit) expense                 1,184 (2,254) (1,701)  
NET INCOME (LOSS) $ 353 $ 2,023 $ (380) $ 644 4,549 $ (4,264) $ 483 $ (1,165) 2,640 (396) (6,142)  
Scenario, Previously Reported                        
Statement of Financial Position [Abstract]                        
Prepaid Expense and Other Assets, Current         4,241         4,241    
Other assets         689         689    
Assets         343,340         343,340    
Current pharma contract liability         0         0    
Long-term pharma contract liability         0         0    
Deferred income tax liability, net         6,307         6,307    
Stockholders' Equity Attributable to Parent         172,918         172,918    
Liabilities and Equity         343,340         343,340    
Income Statement [Abstract]                        
Total Revenue                   258,611 244,083  
Gross Profit                   120,316 110,379  
Total operating expenses                   117,992 107,805  
Income from Operations                   2,324 2,574  
Interest expense                   5,540 9,998  
Other expense (income)                   265 0  
Income tax (benefit) expense                   (2,635) (1,701)  
NET INCOME (LOSS)                   (846) (5,723)  
Accounting Standards Update 2014-09 | Restatement Adjustment                        
Statement of Financial Position [Abstract]                        
Prepaid Expense and Other Assets, Current         912         912    
Other assets         202         202    
Assets         1,114         1,114    
Current pharma contract liability         1,406         1,406    
Long-term pharma contract liability         283         283    
Deferred income tax liability, net         381         381    
Stockholders' Equity Attributable to Parent         (956)         (956)    
Liabilities and Equity         $ 1,114         1,114    
Income Statement [Abstract]                        
Total Revenue                   (18,360) (12,275)  
Gross Profit                   (18,360) (12,275)  
Total operating expenses                   (18,938) (11,856)  
Income from Operations                   578 (419)  
Interest expense                   0 0  
Other expense (income)                   (253) 0  
Income tax (benefit) expense                   381 0  
NET INCOME (LOSS)                   450 (419)  
Clinical Services                        
Income Statement [Abstract]                        
Total Revenue                 241,873 213,097 210,159  
Clinical Services | Scenario, Previously Reported                        
Income Statement [Abstract]                        
Total Revenue                   231,748 222,015  
Clinical Services | Accounting Standards Update 2014-09 | Restatement Adjustment                        
Income Statement [Abstract]                        
Total Revenue                   (18,651) (11,856)  
Pharma Services                        
Income Statement [Abstract]                        
Total Revenue                 $ 34,868 27,154 21,649  
Pharma Services | Scenario, Previously Reported                        
Income Statement [Abstract]                        
Total Revenue                   26,863 22,068  
Pharma Services | Accounting Standards Update 2014-09 | Restatement Adjustment                        
Income Statement [Abstract]                        
Total Revenue                   $ 291 $ (419)